Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

September 23, 2009 08:30 ET

Stem Cell Therapeutics Corp. Announces That Dr. Alan Moore Will Present a Novel, Drug-Based Approach to Neuron Regeneration at the 2009 World Stem Cell Summit

CALGARY, ALBERTA--(Marketwire - Sept. 23, 2009) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced that Dr. Alan Moore, President and CEO, will be featured in today's panel discussion "Commercialization of Stem Cells and International Market Trends" at the 2009 World Stem Cell Summit being held in Baltimore, Maryland, September 21-23.

Dr. Alan Moore, President and CEO of SCT, commented as follows:

"I am pleased to be a part of this 'state of the industry' discussion with fellow regenerative medicine and stem cell business leaders. This is an exciting and interesting time for stem cell related therapies and I feel our drug-based treatment offers a unique alternative to stem cell based therapies for regenerative medicine."

About the World Stem Cell Summit ( The World Stem Cell Summit unites the stem cell universe of researchers, ReGEN industry leaders, funders, medical philanthropies, policy-makers, advocates, educators and regulators to chart the future of regenerative medicine. The comprehensive, multi-track program covers advanced science, commercial perspectives, disease progress reports and in-depth reviews of policy, law, ethics, regulatory issues and global economic development. The 2009 Summit will feature 125 presenting experts, attendees from 25 countries and representatives from more 200 sponsors, supporting organizations and media partners, at the preeminent international networking event.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information